Outpatient Treatment of Systolic Heart Failure

JOHN R. MCCONAGHY, M.D., Ohio State University Family Practice Residency Program, Columbus, Ohio
STEVEN R. SMITH, M.S., R.PH., B.C.P.S., Toledo Hospital Family Practice Residency Program, Toledo, Ohio

Optimal outpatient treatment of systolic heart failure has three goals that should be pursued simultaneously: (1) control of risk factors for the development and progression of heart failure, (2) treatment of heart failure, and (3) education of patients. Control of risk factors includes treating hypertension, diabetes, and coronary artery disease, and eliminating the use of alcohol and tobacco. All patients with heart failure should be taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker. In the absence of contraindications, an ACE inhibitor is preferred. In most patients, physicians should consider adding a beta blocker to ACE-inhibitor therapy. In patients with severe heart failure, spironolactone is a useful addition to baseline drug therapy, as is carvedilol (substitute carvedilol if patient is already taking a beta blocker). Patients with stable heart failure should be encouraged to begin and maintain a regular aerobic exercise program. Digoxin therapy may reduce the likelihood of hospitalization but does not reduce mortality. It must be monitored closely, with a target dosage level of 0.5 to 1.1 ng per mL. Symptoms may be controlled with the use of diuretics and restricted dietary sodium. Finally, patient education, with the patient’s active participation in the care, is a key strategy in the management of heart failure. Periodic follow-up between scheduled office visits, which is essential in the long-term management of heart failure, may include telephone calls from the office nurse, maintenance of a daily symptom and weight diary, and participation in a disease-management program. (Am Fam Physician 2004;70:2157-64,2171-2. Copyright© 2004 American Academy of Family Physicians.)

Data Sources
Articles were identified through an English-language search of MEDLINE and Cochrane databases from 1995 to January 2004, using the terms “heart failure” and “congestive heart failure.” Randomized controlled trials (RCTs), systematic reviews, and evidence-based clinical practice guidelines were included in this review.

Pharmacologic Treatment
ACE INHIBITORS
ACE inhibitors decrease the rate of mortality in all patients with systolic heart failure. Fifty-two four patients would need to be treated for more than 90 days to prevent one death. There also is a reduction in the combined end points of death and hospitalization.
caused by heart failure (number needed to treat [NNT], 11) over four to five years, regardless of severity, although this benefit seems to favor patients in the more severe New York Heart Association (NYHA) classes. Several studies\(^6\)\(^,\)\(^7\) have demonstrated good tolerability to ACE-inhibitor therapy, with dropout rates of 15 to 30 percent, mainly because of dizziness, altered taste, hypotension, hyperkalemia, and cough.

**ANGIOTENSIN-RECEPTOR BLOCKERS**

Angiotensin-receptor blockers (ARBs) are comparable to ACE inhibitors in reducing all-cause mortality and heart failure–related hospitalizations in patients with NYHA classes II and III heart failure.\(^6\)\(^,\)\(^7\) ARBs are more expensive than ACE inhibitors, but because they do not cause cough, they are a reasonable alternative in patients who are unable to tolerate ACE-inhibitor therapy.

One recent study\(^10\) suggests that adding an ARB to ACE-inhibitor therapy provides further mortality benefit in selected patients. In this trial of patients with NYHA classes II to IV heart failure, candesartan added to existing ACE-inhibitor therapy reduced cardiovascular deaths (NNT, 28 over 3.5 years) and heart failure–related hospital admissions (NNT, 27 over 3.5 years). However, in a second study\(^32\) of patients with myocardial infarction complicated by heart failure, no benefit was found from this combination over use of an ACE inhibitor alone.

**BETA BLOCKERS**

Three beta blockers, bisoprolol (Zebeta), metoprolol (Toprol XL), and carvedilol (Coreg), reduce mortality in patients with heart failure who already are taking an ACE inhibitor and/or a diuretic.\(^11\)\(^-\)\(^13\) Smaller studies of older beta blockers suggest that, in patients with NYHA classes I to II heart failure and ischemic heart disease, mortality is reduced with propranolol therapy,\(^14\) and worsening heart failure is reduced, with a trend toward improved survival in patients taking atenolol who have an ejection fraction of less than 25 percent.\(^15\)

### TABLE 1

**Outpatient Treatment of Heart Failure: Evidence-Based Summary**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Strength of recommendation</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitors(^5)(^-)(^7)</td>
<td>A</td>
<td>If tolerated, should be the initial baseline treatment in all patients with heart failure, regardless of NYHA class</td>
</tr>
<tr>
<td>ARBs(^8)(^-)(^10)</td>
<td>A</td>
<td>Benefits similar to those of ACE inhibitors; useful in patients who cannot tolerate ACE inhibitors</td>
</tr>
<tr>
<td>Aerobic exercise(^7)</td>
<td>A</td>
<td>Decreases hospitalization and improves quality of life</td>
</tr>
<tr>
<td>Comprehensive, multidisciplinary outpatient follow-up(^27)(^,)(^28)</td>
<td>A</td>
<td>Decreases hospitalization for heart failure</td>
</tr>
<tr>
<td>Beta blockers(^11)(^-)(^16)</td>
<td>A</td>
<td>Beneficial in most patients with heart failure; usually added to ACE inhibitors or ARBs</td>
</tr>
<tr>
<td>Carvedilol (Coreg)(^17)</td>
<td>A</td>
<td>Proven benefit in moderate to severe heart failure (i.e., NYHA classes II to IV); benefit in severe heart failure (i.e., NYHA classes III to IV) where other beta blockers do not have proven benefit</td>
</tr>
<tr>
<td>Spironolactone (Aldactone)(^18)</td>
<td>A</td>
<td>Proven benefit in severe heart failure (i.e., NYHA classes III or IV); severe hyperkalemia is an important safety concern.</td>
</tr>
<tr>
<td>Eplerenone (Inspra)(^19)</td>
<td>A</td>
<td>Reduces mortality in patients with left ventricular dysfunction following myocardial infarction</td>
</tr>
<tr>
<td>Hydralazine (Apresoline) plus isosorbide dinitrate (Sorbitrate)(^19)(^,)(^20)</td>
<td>A</td>
<td>Combination beneficial in all classes of heart failure. Use is limited by poor tolerability.</td>
</tr>
<tr>
<td>Digoxin(^21)(^-)(^24)</td>
<td>B</td>
<td>May reduce the number of hospitalizations for heart failure; no mortality benefit; narrow therapeutic window</td>
</tr>
<tr>
<td>Diuretics(^4)(^,)(^25)</td>
<td>C</td>
<td>Useful for control of symptoms and fluid and sodium levels</td>
</tr>
<tr>
<td>Dietary sodium restriction(^4)(^,)(^27)</td>
<td>C</td>
<td>Recommended as standard practice, but there are no morbidity or mortality data from randomized controlled trials</td>
</tr>
</tbody>
</table>

ACE = angiotensin-converting enzyme; NYHA = New York Heart Association; ARBs = angiotensin-receptor blockers.

Information from references 4 through 29.
death (NNT, 24 and 35, respectively, over one to two years), regardless of severity as measured by the NYHA classification.\(^\text{16}\)

Although carvedilol has been shown to be beneficial in patients with mild to moderate heart failure, it also has been studied specifically in patients with chronic, severe heart failure.\(^\text{17}\) When added to existing heart failure treatment, carvedilol, in an average dosage of 37 mg per day, decreased mortality (NNT, 18 for 10 months) and lowered the combination of mortality and hospitalization in patients with worsening heart failure (NNT, 13 for 10 months).

The choice of beta blocker remains uncertain. In a recent trial,\(^\text{33}\) patients with NYHA classes II to IV heart failure who were treated with carvedilol had greater reductions in mortality (NNT, 18 for 10 months) and cardiovascular mortality (NNT, 16 over five years) than those treated with metoprolol, but hypotension was more common among the carvedilol group (14 versus 11 percent). However, the target dosage of metoprolol used in this study was 100 mg per day rather than the more commonly studied dosage of 200 mg per day.

### SPIRONOLACTONE

Adding spironolactone (Aldactone), a nonselective aldosterone inhibitor, to standard care can benefit patients with moderate to severe heart failure (NYHA classes III to IV).\(^\text{18}\) Spironolactone in dosages ranging from 25 mg every other day to 50 mg a day reduces mortality (NNT, nine for two years) and hospitalization for worsening heart failure (NNT, three for two years). The most common serious adverse event among patients taking spironolactone is hyperkalemia, especially in the setting of chronic renal insufficiency, and 10 percent of men taking spironolactone experience breast pain and gynecomastia. Eplerenone (Inspra) is a new, more selective aldosterone inhibitor that has been shown to reduce all-cause mortality following myocardial infarction with left ventricular dysfunction (NNT, 43 for 16 months). This medication has not been studied in patients with chronic heart failure who are not in the postmyocardial infarction period.\(^\text{19}\)

### HYDRAZINE PLUS ISOSORBIDE DINITRATE

The combination of hydralazine (Apresoline) and isosorbide dinitrate (Sorbitrate) reduces mortality in patients...
with heart failure, but tolerability is an issue. In earlier trials, men with symptoms of heart failure that were controlled with digoxin and diuretics and treated with hydralazine (average dosage, 270 mg per day) plus isosorbide dinitrate (average dosage, 136 mg per day) had a decrease in all-cause mortality of 28 percent (NNT, 19 for six years).

A more recent trial comparing this combination with enalapril in a dosage of 20 mg per day showed no difference in all-cause mortality between these two groups over three years. However, more than 30 percent of the patients stopped taking the hydralazine, the nitrate, or both, because of side effects.

**DIGOXIN**

Digoxin is effective in relieving symptoms of heart failure in the absence of dysrhythmias, but no studies have demonstrated that it reduces mortality. Patients taking digoxin are less likely to be hospitalized for worsening heart failure (NNT, 27 to 114 over three years), and their heart failure symptoms may worsen if digoxin is withdrawn.

Compared with patients receiving placebo, patients taking digoxin are twice as likely to be hospitalized for suspected digoxin toxicity (number needed to harm [NNH], 52). Further analysis of these data suggests that achieving a serum digoxin level of 0.5 to 0.8 mg per mL (0.6 to 1.0 nmol per L) may be most beneficial; levels from 1.1 to 1.5 mg per mL (1.4 to 1.9 nmol per L) were associated with increased heart failure–related mortality. Similarly, post hoc analysis of these data by sex suggests that while there was no difference in all-cause mortality in men, women randomized to digoxin actually had a higher rate of all-cause mortality (NNH, 18 over three years).

**DIURETICS**

Diuretics are a mainstay of the symptomatic treatment of heart failure. Short-term studies have shown that diuretics improve the symptoms of sodium and fluid retention, and increase exercise tolerance and cardiac function, regardless of NYHA classification. No studies have examined the effects of diuretics on morbidity and mortality.

**ANTIPLATELET THERAPY AND ANTICOAGULATION**

Although patients with heart failure have an increased risk of thromboembolic events (i.e., stroke, pulmonary embolism, and deep venous thrombosis) of 1.6 to 3.2 percent per year, results of a systematic review showed that antiplatelet therapy (primarily aspirin) is not useful in preventing thromboembolism in patients with heart failure in sinus rhythm and may even be harmful. This review also raised a concern that use of aspirin may mitigate the benefit of ACE inhibitors.

Published data do not support the routine use of anticoagulants (e.g., warfarin [Coumadin]) in patients with heart failure and sinus rhythm who do not have demonstrated left ventricular thrombus; the clinical decision should be based on individual risks and benefits. Anticoagulation is recommended for use in patients with heart failure and concomitant atrial fibrillation or a previous thromboembolic event.

**Nonpharmacologic Management**

**DIETARY SODIUM RESTRICTION**

Restricting sodium intake to 2 g or less per day can aid in the control of fluid status and the symptoms of heart failure. No studies have examined the effect of dietary sodium restriction, alone or in combination with pharmacologic treatments, on morbidity or mortality.

**EXERCISE**

Moderate exercise (i.e., at 60 percent of maximum exercise capacity on a stationary bicycle for two to three hours per week) improves quality of life, decreases mortality (NNT, four for 14 months), and decreases hospital readmissions for heart failure (NNT, five for 14 months) in patients with stable chronic heart failure.

**MULTIDISCIPLINARY, DISEASE-MANAGEMENT APPROACH**

A multidisciplinary, disease-management approach to heart failure includes intensive patient education about the condition and its treatment, dietary assessment and instruction, medication analysis, and follow-up by telephone and home visits. Usually it also includes aggressive management of comorbidities and risk factors, including control of blood glucose levels in patients with diabetes, treatment of hypertension to a target measurement of 140/90 mm Hg (130/80 mm Hg in patients with diabetes and those with chronic renal insufficiency), and lipid management to a target low-density lipoprotein level of less than 100 mg per dL (1 g per L) in high-risk patients and less than 70 mg per dL for very high-risk patients. This approach results in fewer hospitalizations (NNT, five for three months) and reduced cost of care. It also decreases the frequency of unplanned and repeat hospitalizations, and increases functional status and quality of life.

**Treatments that Have No Benefit or Are Harmful**

**CCBS**

While some of the newer, long-acting CCBs such as amlodipine (Norvasc) appear to be safe in the treatment of heart failure, no trials have demonstrated that they lower mortality, decrease hospitalizations, or improve
quality of life in patients with a failing heart. Older, short-acting CCBs can worsen heart failure.4,43

POSITIVE INOTROPIC THERAPY

Intermittent positive inotropic therapy should not be used in patients with heart failure in the outpatient setting. RCTs of oral milrinone (Primacor) demonstrate an increase in mortality, an increase in hospitalizations for worsening heart failure, and more serious side effects.44

Prognosis

Despite the increased rate of survival in patients with coronary heart disease in recent decades, the overall prognosis related to heart failure has not improved.45 Mortality data derived from several different studies, the largest of which was the Framingham Heart Study,46 have shown that heart failure remains highly lethal, with a five-year survival rate of 25 percent in men and 38 percent in women with NYHA classes II to IV heart failure. Mortality data from the placebo arms of intervention trials show an average 18 percent one-year mortality.

A recent population-based study47 of patients with a new diagnosis of heart failure showed survival rates of only 62 percent at 12 months and 57 percent at 18 months. Although predicting the likelihood of survival in patients with heart failure remains challenging, a recent validated clinical prediction rule provides some guidance. This rule offers a prediction of 30-day and one-year mortality for patients hospitalized with heart failure based on a scoring system that takes into account such factors as age, systolic blood pressure, and renal function.48

Suggested Management of Heart Failure

Although the optimal sequence of pharmacologic interventions in the treatment of heart failure has not been examined in RCTs, recommendations can be made based on the existing evidence in heart failure management (Figure 1).29 This approach can be divided into the following four categories that should be addressed simultaneously.

RISKS FOR THE DEVELOPMENT AND PROGRESSION OF HEART FAILURE

Although they are not specifically discussed in this article, the risks for the development and advancement of heart failure should be addressed.4 This step includes identifying and treating hypertension, diabetes, thyroid disease, hyperlipidemia, atherosclerotic and coronary artery disease, and myocardial ischemia, and eliminating the use of alcohol and tobacco.

TREATMENT OF HEART FAILURE

All patients with heart failure should receive one or more medications that affect the disease process, based on the preponderance of evidence that they decrease morbidity.

Figure 1. Algorithm for the outpatient treatment of systolic heart failure. Activities in the three columns should occur simultaneously. (ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; CAD = coronary artery disease; NYHA = New York Heart Association)

and mortality. These medications include ACE inhibitors (or ARBs) and beta blockers. In most patients, ACE inhibitors should be the initial baseline treatment in heart failure if they are tolerated—regardless of NYHA class. This recommendation is based on the proven track record of ACE inhibitors and the observation that most recent heart failure trials include patients already taking these medications.

### The Authors

JOHN R. MCCONAGHY, M.D., F.A.A.F.P., is program director of the Ohio State University Family Practice Residency, Columbus. He received his medical degree from the University of Pittsburgh School of Medicine and completed residency training at David Grant USAF Medical Center Family Practice Residency, Travis Air Force Base, Calif.

STEVEN R. SMITH, M.S., R.PH., B.C.P.S, is a clinical pharmacist on faculty at the Toledo (Ohio) Hospital Family Practice Residency Program. He received his pharmacy degrees from Ohio Northern University Raabe College of Pharmacy, Ada, and the University of Toledo College of Pharmacy.

Address correspondence to John R. McConaghy, M.D., The Ohio State University Family Practice Residency Program, 2231 N. High St., Columbus, OH 43201 (e-mail: McConaghy-1@medctr.osu.edu). Reprints are not available from the authors.

**TABLE 3**

Converting Patients to Carvedilol from Beta-Blocker Therapy

<table>
<thead>
<tr>
<th>Beta-blocker dosage</th>
<th>Carvedilol dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>No overlap method</td>
<td></td>
</tr>
<tr>
<td>Not currently receiving a beta blocker</td>
<td>Start carvedilol in a dosage of 3.125 mg twice daily; titrate dosage every one to two weeks to the maximum tolerated dosage or 25 mg twice daily.</td>
</tr>
<tr>
<td>Metoprolol (Toprol XL), 50 mg per day, or atenolol (Tenormin), 50 mg per day</td>
<td>Start carvedilol in a dosage of 6.25 mg twice daily; titrate dosage every one to two weeks.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Overlap method</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Atenolol, 200 mg per day</td>
<td>Add carvedilol in a dosage of 3.125 mg twice daily for two weeks, then reduce dosage of atenolol to 150 mg daily for two weeks, then double the carvedilol dosage every two weeks while reducing the daily dosage of atenolol by 50 mg. When dosage of atenolol reaches 50 mg, decrease dosage to 25 mg daily for two weeks and discontinue.</td>
</tr>
</tbody>
</table>

| Metoprolol, 100 to 200 mg per day | Add carvedilol in a dosage of 3.125 mg twice daily for two weeks, then double the carvedilol dosage every two weeks while reducing the daily metoprolol dosage by 50 mg. Discontinue metoprolol after two weeks of 50 mg per day. |

Information from reference 49.

ARBs have efficacy similar to that of ACE inhibitors and are an adequate alternative. Beta blockers (i.e., metoprolol and bisoprolol) also are useful as a baseline treatment added to ACE inhibitors in most patients with heart failure and may be especially useful in the settings of tachydysrhythmias and following myocardial infarction.

For severe heart failure (NYHA classes III to IV), spironolactone and carvedilol are useful additions to baseline drug therapy that improve patient survival. Carvedilol may be added if a beta blocker is not used currently. If the patient is taking a beta blocker and is clinically stable, a careful plan should be followed while switching the patient to carvedilol. Alternatives are presented in Table 3. The dosage of carvedilol should be increased every two weeks as the patient tolerates or to a maximum dosage of 25 mg twice daily.

Patients with stable heart failure should be encouraged to begin and maintain a regular aerobic exercise program. The level of exercise can range from brief, symptom-limited exercise to moderate exercise (at 60 percent of capacity) for three or more hours per week.

The role of digoxin in the treatment of a failing heart without dysrhythmias is unclear. Patients already receiving digoxin probably should be maintained on this agent. Initiating therapy with digoxin is unlikely to
affect mortality but may improve symptoms and reduce the risk of hospitalization for heart failure. If used, a target serum level of 0.5 to 0.8 ng per mL is appropriate.

CONTROL OF SYMPTOMS

The symptomatic treatment of heart failure includes the use of diuretics and restriction of dietary sodium to control fluid volume status. Symptom control should be accomplished concomitantly with the basic pharmacologic disease management outlined above.

CLOSE FOLLOW-UP

Comprehensive follow-up, with the patient as an active participant, is a key strategy in the long-term care of patients with heart failure. This aspect of management should include educating patients about their disease process; teaching them about their dietary and pharmacologic treatments; showing them how to monitor their weight, symptoms, and blood pressure; educating them about when to seek care; and providing periodic telephone follow-up between scheduled office visits. This sort of comprehensive, systematic follow-up can be part of a formal disease-management program or may be implemented in a well-organized primary care practice. No data exist to indicate the appropriate timing of referral to a cardiologist, but referral should be considered in patients with more complex conditions.

The authors indicate that they do not have any conflicts of interest.

Sources of funding: none reported.

REFERENCES

### Strength of Recommendation

<table>
<thead>
<tr>
<th>Key clinical recommendations</th>
<th>Label</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin-converting enzyme (ACE) inhibitors should be the initial baseline treatment in all patients with heart failure, if tolerated, regardless of New York Heart Association (NYHA) class.</td>
<td>A</td>
<td>5-7</td>
</tr>
<tr>
<td>Angiotensin-receptor blockers have benefits similar to those of ACE inhibitors and are useful in patients who cannot tolerate ACE inhibitors.</td>
<td>A</td>
<td>8-10</td>
</tr>
<tr>
<td>Aerobic exercise is recommended because it decreases the number of hospitalizations and improves quality of life.</td>
<td>A</td>
<td>26</td>
</tr>
<tr>
<td>Comprehensive, multidisciplinary outpatient follow-up is recommended because it decreases the rate of hospitalization for heart failure.</td>
<td>A</td>
<td>27, 28</td>
</tr>
<tr>
<td>Beta blockers are recommended for most patients with heart failure; they also may be useful if there are concomitant tachyarrhythmias following myocardial infarction.</td>
<td>A</td>
<td>11-16</td>
</tr>
<tr>
<td>Carvedilol reduces mortality in patients with severe heart failure (i.e., NYHA classes III or IV).</td>
<td>A</td>
<td>17</td>
</tr>
<tr>
<td>Spironolactone reduces mortality in patients with severe heart failure (i.e., NYHA classes III or IV); patients must be monitored closely for hyperkalemia.</td>
<td>A</td>
<td>18</td>
</tr>
<tr>
<td>Eplerenone reduces mortality in patients with left ventricular dysfunction following myocardial infarction.</td>
<td>A</td>
<td>19</td>
</tr>
<tr>
<td>Hydralazine plus isosorbide dinitrate is beneficial, but its use is limited by poor tolerability.</td>
<td>A</td>
<td>19, 20</td>
</tr>
<tr>
<td>Digoxin is an option that may reduce the number of hospitalizations but does not reduce the rate of mortality.</td>
<td>B</td>
<td>21-24</td>
</tr>
<tr>
<td>Diuretics are useful for fluid, sodium, and symptom control.</td>
<td>B</td>
<td>4, 25</td>
</tr>
<tr>
<td>Dietary sodium restriction is recommended, but studies have not measured patient-oriented outcomes.</td>
<td>C</td>
<td>4, 37</td>
</tr>
</tbody>
</table>

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 2055 for more information.